Aquestive Therapeutics, Inc. (AQST) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Abeona Therapeutics, Inc.

MediWound Ltd.

Milestone Pharmaceuticals, Inc.

Pyxis Oncology, Inc.

Aquestive Therapeutics, Inc.

DiaMedica Therapeutics, Inc.

Relmada Therapeutics, Inc.

Achieve Life Sciences, Inc.

MediciNova, Inc.

Atossa Therapeutics, Inc.

GlycoMimetics, Inc.

Why is Aquestive Therapeutics, Inc. ?

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

Poor long term growth as Net Sales has grown by an annual rate of -4.67% and Operating profit at -13.01% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -2.40

The company has declared Negative results for the last 3 consecutive quarters

NET SALES(HY) At USD 22.81 MM has Grown at -32.2%
OPERATING CASH FLOW(Y) Lowest at USD -50.45 MM
DEBT-EQUITY RATIO (HY) Highest at 4.89 %

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 44.73%, its profits have fallen by -101.9%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aquestive Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Aquestive Therapeutics, Inc.

44.73%

0.49

89.99%

S&P 500

14.9%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-4.67%

EBIT Growth (5y)

-13.01%

EBIT to Interest (avg)

-2.40

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.84

Sales to Capital Employed (avg)

2.81

Tax Ratio

0.03%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

73.76%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-124.15

EV to EBIT

-9.06

EV to EBITDA

-9.15

EV to Capital Employed

-57.32

EV to Sales

11.65

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

3What is working for the Company

NET PROFIT(HY)

Higher at USD -28.99 MM

CASH AND EQV(HY)

Highest at USD 189.6 MM

-23What is not working for the Company

NET SALES(HY)

At USD 22.81 MM has Grown at -32.2%

OPERATING CASH FLOW(Y)

Lowest at USD -50.45 MM

DEBT-EQUITY RATIO (HY)

Highest at 4.89 %

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.04 times

PRE-TAX PROFIT(Q)

Fallen at -34.21%

NET PROFIT(Q)

Fallen at -34.21%

Here's what is working for Aquestive Therapeutics, Inc.

Cash and Eqv

Highest at USD 189.6 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Here's what is not working for Aquestive Therapeutics, Inc.

Net Sales

At USD 22.81 MM has Grown at -32.2%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (USD MM)

Operating Cash Flow

Lowest at USD -50.45 MM and Fallen

In each year in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (USD MM)

Pre-Tax Profit

Fallen at -34.21%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Net Profit

Fallen at -34.21%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 4.89 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Debtors Turnover Ratio

Lowest at 4.04 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio